Skip to main content
Ankit Mangla, MD, Oncology, Cleveland, OH

Ankit Mangla MD

Oncology•Cleveland, OH

Assistant Professor

Join to View Full Profile

  • 11100 Euclid AveCleveland, OH 44106

  • Phone+1 312-513-7437

Dr. Mangla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Mangla's Full ProfileAlready have an account?

Summary

  • I am a medical oncologist with career interests in melanoma and soft-tissue sarcoma. I am a clinical researcher with a keen interest in bringing immunotherapy related trials. I am PI on several trials which are exploring the role of immunotherapy in both melanoma and sarcoma.

Education & Training

  • Cook County Health and Hospitals System
    Cook County Health and Hospitals SystemFellowship, Hematology and Medical Oncology, 2015 - 2018
  • Cook County Health and Hospitals System
    Cook County Health and Hospitals SystemResidency, Internal Medicine, 2012 - 2015
  • ArMed Forces Medical College Pune
    ArMed Forces Medical College PuneClass of 2007, MBBS

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2017 - 2026
  • IL State Medical License
    IL State Medical License 2015 - 2023
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Highest Clinical Trial Accruals University Hospitals Seidman Cancer Center, 2023
  • Certificate of Appreciation for Leading Accrual of Minority Research Participants in 2022 Case Western Reserve University School of Medicine, 2022

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Net Clinical Benefit of Low Dose Rivaroxaban in Coronary Heart Disease: A Systematic Review and Meta-Analysis
    Ankit Mangla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor
    Ankit Mangla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Predictors and outcomes of thyroid dysfunction with immunotherapy: A single institution observational experience. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than with Anti-PD1 Therapy Alone, but the Occurrence of Adverse Events Is Also Higher
    Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than with Anti-PD1 Therapy Alone, but the Occurrence of Adverse Events Is Also HigherApril 11th, 2024
  • BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
    BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D DayJuly 25th, 2024
  • What Is Cardiac Angiosarcoma?
    What Is Cardiac Angiosarcoma?November 29th, 2021
  • Join now to see all

Committees

  • Member, Southwest Oncology Group Melanoma Committee 2025 - Present
  • Member, Southwest Oncology Group Sarcoma Committee 2023 - Present
  • Member, Protocol Review and Monitoring Committee (Case Western Reserve University) 2020 - Present

Professional Memberships

Other Languages

  • Hindi

External Links

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Ankit Mangla, Dr. Ankit Mangla, MD, Dr. A Mangla